The World’s leading vaccine manufacturer, the Serum Institute of India (SII), on Thursday said the corona vaccine, developed in collaboration with Oxford University and AstraZeneca, is completely safe and effective. The company claims it is being tested in India according to vaccine standards.
The SAI appealed to the people to be patient and said the vaccine was 60-70% effective at bad performance. People have begun to question the early results of defects in the production of this experimental corona vaccine.
AstraZeneca and Oxford have previously claimed that the vaccine was very effective. But the company did not explain why some participants were not given the first dose of the vaccine as previously mentioned.
ALSO READ: Corona was exposed to 7.43 crore people in the country as of August
In fact, the Oxford vaccine has been found to be 90 percent effective at half the dose. 62 is effective at giving full doses. However, the scientific community remains unanswered. But AstraZeneca has made public the shortcoming behind this unique result. Mena Penalos, quoted by Nature Journal AstraZeneca Vice President (BioCenter-Research and Development), said that good results are the wrong outcome. When the vaccine trials began in late April, there was less headache, fatigue and hand pain complaints than those who were vaccinated. Scientists could not understand the reason for this. Therefore, the data of the tests were verified from scratch.
PM Modi to visit SAI
Meanwhile, Prime Minister Narendra Modi will visit Pune’s Serum Institute of India (SII) on Saturday. A senior official gave this information on Thursday. SAI has partnered with global ceramic manufacturer AstraZeneca and the University of Oxford for the Kovid-19 vaccine. “We have received a confirmation on Prime Minister Modi’s visit to the Serum Institute of India on Saturday, but a detailed explanation of his program (minute-to-minute) has not yet been received,” said Punelayat Saurabh Rao The prime minister had said on Tuesday that he was likely to visit Pune, and if that happens, the aim is to review the mechanism of vaccine preparation, production and distribution procedures for coronavirus infection.
.
